Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 375

1.

Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis.

Ntaios G, Swaminathan B, Berkowitz SD, Gagliardi RJ, Lang W, Siegler JE, Lavados P, Mundl H, Bornstein N, Meseguer E, Amarenco P, Cucchiara B, Camps-Renom P, Makaritsis K, Korompoki E, Papavasileiou V, Marti-Fabregas J, Milionis H, Vemmos K, Connolly SJ, Hart RG; NAVIGATE ESUS Investigators.

Stroke. 2019 Aug 12:STROKEAHA119025168. doi: 10.1161/STROKEAHA.119.025168. [Epub ahead of print]

PMID:
31401971
2.

Disability after minor stroke and TIA: A secondary analysis of the SOCRATES trial.

Cucchiara B, George DK, Kasner SE, Knutsson M, Denison H, Ladenvall P, Amarenco P, Johnston SC.

Neurology. 2019 Aug 13;93(7):e708-e716. doi: 10.1212/WNL.0000000000007936. Epub 2019 Jul 11.

PMID:
31296654
3.

Japanese Versus Non-Japanese Patients with Transient Ischemic Attack or Minor Stroke: Subanalysis of TIA registry.org.

Uchiyama S, Hoshino T, Sissani L, Linsay MT, Kamiyama K, Nakase T, Kitagawa K, Minematsu K, Todo K, Okada Y, Nakagawara J, Nagata K, Yamagami H, Yamaguchi T, Amarenco P; TIAregistry.org Investigators.

J Stroke Cerebrovasc Dis. 2019 Aug;28(8):2232-2241. doi: 10.1016/j.jstrokecerebrovasdis.2019.05.005. Epub 2019 Jun 7.

4.

Non-cardioembolic stroke/transient ischaemic attack in Asians and non-Asians: A post-hoc analysis of the PERFORM study.

Hoshino T, Sissani L, Labreuche J, Bousser MG, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, Gabriel Steg P, Vicaut E, Amarenco P.

Eur Stroke J. 2019 Mar;4(1):65-74. doi: 10.1177/2396987318797245. Epub 2018 Aug 24.

5.

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.

Fruchart JC, Santos RD, Aguilar-Salinas C, Aikawa M, Al Rasadi K, Amarenco P, Barter PJ, Ceska R, Corsini A, Després JP, Duriez P, Eckel RH, Ezhov MV, Farnier M, Ginsberg HN, Hermans MP, Ishibashi S, Karpe F, Kodama T, Koenig W, Krempf M, Lim S, Lorenzatti AJ, McPherson R, Nuñez-Cortes JM, Nordestgaard BG, Ogawa H, Packard CJ, Plutzky J, Ponte-Negretti CI, Pradhan A, Ray KK, Reiner Ž, Ridker PM, Ruscica M, Sadikot S, Shimano H, Sritara P, Stock JK, Su TC, Susekov AV, Tartar A, Taskinen MR, Tenenbaum A, Tokgözoğlu LS, Tomlinson B, Tybjærg-Hansen A, Valensi P, Vrablík M, Wahli W, Watts GF, Yamashita S, Yokote K, Zambon A, Libby P.

Cardiovasc Diabetol. 2019 Jun 4;18(1):71. doi: 10.1186/s12933-019-0864-7. Review.

6.

Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial.

Easton JD, Denison H, Evans SR, Knutsson M, Amarenco P, Albers GW, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KL, Johnston SC; SOCRATES Steering Committee and Investigators.

Int J Stroke. 2019 May 15:1747493019851282. doi: 10.1177/1747493019851282. [Epub ahead of print]

PMID:
31092152
7.

Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe.

Kotseva K, Gerlier L, Sidelnikov E, Kutikova L, Lamotte M, Amarenco P, Annemans L.

Eur J Prev Cardiol. 2019 Jul;26(11):1150-1157. doi: 10.1177/2047487319834770. Epub 2019 Apr 6.

PMID:
30955367
8.

Impact of Low Ankle-Brachial Index on the Risk of Recurrent Vascular Events.

Abboud H, Monteiro Tavares L, Labreuche J, Arauz A, Bryer A, Lavados PM, Massaro A, Munoz Collazos M, Steg PG, Yamout BI, Vicaut E, Amarenco P.

Stroke. 2019 Apr;50(4):853-858. doi: 10.1161/STROKEAHA.118.022180.

PMID:
30852970
9.

Acute dual antiplatelet therapy for minor ischaemic stroke or transient ischaemic attack.

Wang Y, Johnston SC, Bath PM, Grotta JC, Pan Y, Amarenco P, Wang Y, Simon T, Kim JS, Jeng JS, Liu L, Lin Y, Wong KSL, Wang D, Li H.

BMJ. 2019 Feb 28;364:l895. doi: 10.1136/bmj.l895. No abstract available.

10.

Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial.

Molina CA, Johnston SC, Ladenvall P, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Knutsson M, Minematsu K, Röther J, Wang Y, Wong KSL; SOCRATES Steering Committee and Investigators.

Stroke. 2019 Mar;50(3):675-682. doi: 10.1161/STROKEAHA.118.022675. Erratum in: Stroke. 2019 Apr;50(4):e118.

PMID:
30776996
11.

The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial: Rationale and design.

Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y; THALES Investigators.

Int J Stroke. 2019 Feb 12:1747493019830307. doi: 10.1177/1747493019830307. [Epub ahead of print]

PMID:
30747613
12.

Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study.

Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG, Camm AJ.

Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):70-79. doi: 10.1093/ehjcvp/pvy041.

PMID:
30423165
13.

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.

Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, Ginsberg H, Hiatt WR, Ishibashi S, Koenig W, Nordestgaard BG, Fruchart JC, Libby P, Ridker PM.

Am Heart J. 2018 Dec;206:80-93. doi: 10.1016/j.ahj.2018.09.011. Epub 2018 Sep 29. Review.

14.

Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke.

Amarenco P; Steering Committee and Investigators of the TIAregistry.org Project.

N Engl J Med. 2018 Oct 18;379(16):1580-1581. doi: 10.1056/NEJMc1808913. No abstract available.

PMID:
30332572
15.

Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.

Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG.

Europace. 2019 Mar 1;21(3):421-427. doi: 10.1093/europace/euy160.

PMID:
30052894
16.

Global Prospective Safety Analysis of Rivaroxaban.

Kirchhof P, Radaideh G, Kim YH, Lanas F, Haas S, Amarenco P, Turpie AGG, Bach M, Lambelet M, Hess S, Camm AJ; Global XANTUS program Investigators.

J Am Coll Cardiol. 2018 Jul 10;72(2):141-153. doi: 10.1016/j.jacc.2018.04.058.

17.

Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial.

Wong KSL, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Himmelmann A, Kasner SE, Knutsson M, Ladenvall P, Minematsu K, Molina CA, Wang Y, Johnston SC; SOCRATES Steering Committee and Investigators.

Stroke. 2018 Jul;49(7):1678-1685. doi: 10.1161/STROKEAHA.118.020553. Epub 2018 Jun 18.

18.

Efficacy of Endovascular Therapy in Acute Ischemic Stroke Depends on Age and Clinical Severity.

Le Bouc R, Clarençon F, Meseguer E, Lapergue B, Consoli A, Turc G, Naggara O, Duong DL, Servan J, Reiner P, Labeyrie MA, Fisselier M, Blanc R, Farhat W, Pires C, Zuber M, Obadia M, Mazighi M, Pico F, Mas JL, Amarenco P, Samson Y; Paris Stroke Consortium.

Stroke. 2018 Jul;49(7):1686-1694. doi: 10.1161/STROKEAHA.117.020511. Epub 2018 Jun 18.

PMID:
29915120
19.

Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.

Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O'Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ; NAVIGATE ESUS Investigators.

N Engl J Med. 2018 Jun 7;378(23):2191-2201. doi: 10.1056/NEJMoa1802686. Epub 2018 May 16.

20.

Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke.

Amarenco P, Lavallée PC, Monteiro Tavares L, Labreuche J, Albers GW, Abboud H, Anticoli S, Audebert H, Bornstein NM, Caplan LR, Correia M, Donnan GA, Ferro JM, Gongora-Rivera F, Heide W, Hennerici MG, Kelly PJ, Král M, Lin HF, Molina C, Park JM, Purroy F, Rothwell PM, Segura T, Školoudík D, Steg PG, Touboul PJ, Uchiyama S, Vicaut É, Wang Y, Wong LKS; TIAregistry.org Investigators.

N Engl J Med. 2018 Jun 7;378(23):2182-2190. doi: 10.1056/NEJMoa1802712. Epub 2018 May 16.

21.

Corrigendum to "HDL-C, triglycerides and carotid IMT: A meta-analysis of 21,000 patients with automated edge detection IMT measurement" [Atherosclerosis 232 (2014) 65-71].

Touboul PJ, Labreuche J, Bruckert E, Schargrodsky H, Prati P, Tosetto A, Hernandez-Hernandez R, Woo KS, Silva H, Vicaut E, Amarenco P.

Atherosclerosis. 2018 Jun;273:158. doi: 10.1016/j.atherosclerosis.2018.01.025. Epub 2018 Apr 12. No abstract available.

PMID:
29657021
22.

New prospects for PCSK9 inhibition?

Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Borén J, Farnier M, Ference BA, Gielen S, Graham I, Grobbee DE, Hovingh GK, Lüscher TF, Piepoli MF, Ray KK, Stroes ES, Wiklund O, Windecker S, Zamorano JL, Pinto F, Tokgözoglu L, Bax JJ, Catapano AL; European Society of Cardiology/European Atherosclerosis Society Task Force.

Eur Heart J. 2018 Jul 14;39(27):2600-2601. doi: 10.1093/eurheartj/ehy147. No abstract available.

PMID:
29579192
23.

Amyloid Angiopathy in Brain Hemorrhage: A Postmortem Neuropathological-Magnetic Resonance Imaging Study.

Guidoux C, Hauw JJ, Klein IF, Labreuche J, Berr C, Duyckaerts C, Amarenco P.

Cerebrovasc Dis. 2018;45(3-4):124-131. doi: 10.1159/000486554. Epub 2018 Mar 20.

PMID:
29558742
24.

Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial.

Kasner SE, Lavados P, Sharma M, Wang Y, Wang Y, Dávalos A, Shamalov N, Cunha L, Lindgren A, Mikulik R, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi R, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni DS, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, DeVries Basson MM, Endres M, Muir K, Bornstein N, Ozturk S, O'Donnell M, Mundl H, Pater C, Weitz J, Peacock WF, Swaminathan B, Kirsch B, Berkowitz SD, Peters G, Pare G, Themeles E, Shoamanesh A, Connolly SJ, Hart RG; NAVIGATE ESUS Steering Committee and Investigators.

J Stroke Cerebrovasc Dis. 2018 Jun;27(6):1673-1682. doi: 10.1016/j.jstrokecerebrovasdis.2018.01.027. Epub 2018 Mar 7.

25.

Prevalence of Systemic Atherosclerosis Burdens and Overlapping Stroke Etiologies and Their Associations With Long-term Vascular Prognosis in Stroke With Intracranial Atherosclerotic Disease.

Hoshino T, Sissani L, Labreuche J, Ducrocq G, Lavallée PC, Meseguer E, Guidoux C, Cabrejo L, Hobeanu C, Gongora-Rivera F, Touboul PJ, Steg PG, Amarenco P; AMISTAD Investigators.

JAMA Neurol. 2018 Feb 1;75(2):203-211. doi: 10.1001/jamaneurol.2017.3960.

26.

Learning from TARDIS: time for more focused trials in stroke prevention.

Amarenco P.

Lancet. 2018 Mar 3;391(10123):819-821. doi: 10.1016/S0140-6736(17)33309-3. Epub 2017 Dec 20. No abstract available.

27.

Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial.

Ganz P, Amarenco P, Goldstein LB, Sillesen H, Bao W, Preston GM, Welch KMA; SPARCL Steering Committee.

Stroke. 2017 Dec;48(12):3223-3231. doi: 10.1161/STROKEAHA.117.017965. Epub 2017 Nov 7.

PMID:
29114094
28.

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.

Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Borén J, Farnier M, Ference BA, Gielen S, Graham I, Grobbee DE, Hovingh GK, Lüscher TF, Piepoli MF, Ray KK, Stroes ES, Wiklund O, Windecker S, Zamorano JL, Pinto F, Tokgözoglu L, Bax JJ, Catapano AL.

Eur Heart J. 2018 Apr 7;39(14):1131-1143. doi: 10.1093/eurheartj/ehx549. No abstract available.

PMID:
29045644
29.

Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study.

Camm AJ, Turpie AGG, Hess S, Amarenco P, Lambelet M, Haas S, van Eickels M, Kirchhof P; XANTUS Investigators.

Europace. 2018 Jun 1;20(6):e87-e95. doi: 10.1093/europace/eux127.

PMID:
29016755
30.

Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets: S2TOP-BLEED.

Hilkens NA, Algra A, Diener HC, Reitsma JB, Bath PM, Csiba L, Hacke W, Kappelle LJ, Koudstaal PJ, Leys D, Mas JL, Sacco RL, Amarenco P, Sissani L, Greving JP; Cerebrovascular Antiplatelet Trialists' Collaborative Group.

Neurology. 2017 Aug 29;89(9):936-943. doi: 10.1212/WNL.0000000000004289. Epub 2017 Aug 2.

31.

Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.

Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Hill MD, Jonasson J, Kasner SE, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC; SOCRATES Steering Committee and Investigators.

Stroke. 2017 Sep;48(9):2480-2487. doi: 10.1161/STROKEAHA.117.017217. Epub 2017 Jul 18.

PMID:
28720658
32.

Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes).

Easton JD, Aunes M, Albers GW, Amarenco P, Bokelund-Singh S, Denison H, Evans SR, Held P, Jahreskog M, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC; SOCRATES Steering Committee and Investigators.

Circulation. 2017 Sep 5;136(10):907-916. doi: 10.1161/CIRCULATIONAHA.117.028566. Epub 2017 Jun 27.

PMID:
28655834
33.

Differences in Characteristics and Outcomes Between Asian and Non-Asian Patients in the TIAregistry.org.

Hoshino T, Uchiyama S, Wong LKS, Sissani L, Albers GW, Bornstein NM, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Labreuche J, Lavallée PC, Molina C, Rothwell PM, Steg PG, Touboul PJ, Vicaut É, Amarenco P; TIAregistry.org Investigators.

Stroke. 2017 Jul;48(7):1779-1787. doi: 10.1161/STROKEAHA.117.016874. Epub 2017 Jun 5.

PMID:
28584002
34.

Clinical Significance of Isolated Atypical Transient Symptoms in a Cohort With Transient Ischemic Attack.

Lavallée PC, Sissani L, Labreuche J, Meseguer E, Cabrejo L, Guidoux C, Klein IF, Touboul PJ, Amarenco P.

Stroke. 2017 Jun;48(6):1495-1500. doi: 10.1161/STROKEAHA.117.016743. Epub 2017 May 9.

PMID:
28487336
35.

Aspirin's Benefits Were Previously Underestimated and Are Primarily Accrued in the Acute Setting.

Amarenco P, Kim AS.

Stroke. 2017 May;48(5):1438-1440. doi: 10.1161/STROKEAHA.117.015061. Epub 2017 Apr 14. Review. No abstract available.

PMID:
28411262
36.

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.

Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators.

N Engl J Med. 2017 Apr 20;376(16):1527-1539. doi: 10.1056/NEJMoa1701488. Epub 2017 Mar 17.

37.

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.

Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C; SPIRE Investigators.

N Engl J Med. 2017 Apr 20;376(16):1517-1526. doi: 10.1056/NEJMoa1614062. Epub 2017 Mar 17.

38.

Symptomatic Patients Remain at Substantial Risk of Arterial Disease Complications Before and After Endarterectomy or Stenting.

Hobeanu C, Lavallée PC, Rothwell PM, Sissani L, Albers GW, Bornstein NM, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Labreuche J, Molina C, Steg PG, Touboul PJ, Uchiyama S, Vicaut É, Wong LK, Amarenco P; TIAregistry.org Investigators.

Stroke. 2017 Apr;48(4):1005-1010. doi: 10.1161/STROKEAHA.116.015171. Epub 2017 Mar 13.

PMID:
28289241
39.

Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial.

Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Hill MD, Jonasson J, Kasner SE, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC; SOCRATES Steering Committee and Investigators.

Lancet Neurol. 2017 Apr;16(4):301-310. doi: 10.1016/S1474-4422(17)30038-8. Epub 2017 Feb 23.

PMID:
28238711
40.

Specificities of Ischemic Stroke Risk Factors in Arab-Speaking Countries.

Abboud H, Sissani L, Labreuche J, Arauz A, Bousser MG, Bryer A, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Lavados PM, Massaro A, Mattle HP, Munoz Collazos M, Rothwell PM, Steg PG, Vicaut E, Yamouth B, Amarenco P; OPTIC Registry and PERFORM Trial Investigators.

Cerebrovasc Dis. 2017;43(3-4):169-177. doi: 10.1159/000454776. Epub 2017 Feb 15.

41.

The Intracranial-B2LEED3S Score and the Risk of Intracranial Hemorrhage in Ischemic Stroke Patients Under Antiplatelet Treatment.

Amarenco P, Sissani L, Labreuche J, Vicaut E, Bousser MG, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle H, Rothwell PM, Steg PG, Diener HC, Sacco RL, Greving JP, Algra A; PERFORM and PRoFESS Committees and Investigators.

Cerebrovasc Dis. 2017;43(3-4):145-151. doi: 10.1159/000453459. Epub 2017 Jan 14.

42.

Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes).

Wang Y, Minematsu K, Wong KS, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Jonasson J, Molina CA, Johnston SC; SOCRATES Steering Committee and Investigators.

Stroke. 2017 Jan;48(1):167-173. doi: 10.1161/STROKEAHA.116.014891. Epub 2016 Nov 29.

PMID:
27899747
43.

Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy.

Coleman CI, Haas S, Turpie AG, Kuhls S, Hess S, Evers T, Amarenco P, Kirchhof P, Camm AJ; XANTUS Investigators.

Clin Cardiol. 2016 Oct;39(10):565-569. doi: 10.1002/clc.22565. Epub 2016 Jun 30.

44.

Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.

Johnston SC, Amarenco P.

N Engl J Med. 2016 Oct 6;375(14):1395. doi: 10.1056/NEJMc1610106. No abstract available.

PMID:
27705253
45.

Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population.

Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJ, Kastelein JJ, Amarenco P, LaRosa JC, Cramer MJ, Westerink J, Kappelle LJ, de Borst GJ, Visseren FL.

Circulation. 2016 Nov 8;134(19):1419-1429. Epub 2016 Sep 28.

46.

Dysfunctional HDL in acute stroke.

Ortiz-Munoz G, Couret D, Lapergue B, Bruckert E, Meseguer E, Amarenco P, Meilhac O.

Atherosclerosis. 2016 Oct;253:75-80. doi: 10.1016/j.atherosclerosis.2016.08.035. Epub 2016 Aug 26.

PMID:
27591364
47.

Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial.

Hart RG, Sharma M, Mundl H, Shoamanesh A, Kasner SE, Berkowitz SD, Pare G, Kirsch B, Pogue J, Pater C, Peters G, Davalos A, Lang W, Wang Y, Wang Y, Cunha L, Eckstein J, Tatlisumak T, Shamalov N, Mikulik R, Lavados P, Hankey GJ, Czlonkowska A, Toni D, Ameriso SF, Gagliardi RJ, Amarenco P, Bereczki D, Uchiyama S, Lindgren A, Endres M, Brouns R, Yoon BW, Ntaios G, Veltkamp R, Muir KW, Ozturk S, Arauz A, Bornstein N, Bryer A, O'Donnell MJ, Weitz J, Peacock F, Themeles E, Connolly SJ.

Eur Stroke J. 2016 Sep;1(3):146-154. doi: 10.1177/2396987316663049. Epub 2016 Aug 3.

48.

Impact of Initial Diffusion-Weighted Imaging Lesion Growth Rate on the Success of Endovascular Reperfusion Therapy.

Olivot JM, Sissani L, Meseguer E, Inoue M, Labreuche J, Mlynash M, Amarenco P, Mazighi M.

Stroke. 2016 Sep;47(9):2305-10. doi: 10.1161/STROKEAHA.116.013916. Epub 2016 Aug 9.

PMID:
27507867
49.

Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials.

Ridker PM, Amarenco P, Brunell R, Glynn RJ, Jukema JW, Kastelein JJ, Koenig W, Nissen S, Revkin J, Santos RD, Schwartz PF, Yunis C, Tardif JC; Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Investigators.

Am Heart J. 2016 Aug;178:135-44. doi: 10.1016/j.ahj.2016.05.010. Epub 2016 May 28.

50.

Risk of Stroke after Transient Ischemic Attack or Minor Stroke.

Amarenco P; Steering Committee Investigators of the TIAregistry.org.

N Engl J Med. 2016 Jul 28;375(4):387. doi: 10.1056/NEJMc1606657. No abstract available.

PMID:
27464211

Supplemental Content

Loading ...
Support Center